Transcranial random noise stimulation for the acute treatment of depression: a randomized controlled trial

- 5 Stevan Nikolin, Ph.D.^{1,2*}, Angelo Alonzo, Ph.D.^{1,2}, Donel Martin, Ph.D.^{1,2}, Veronica Gálvez,
- 6 MD.^{1,3}, Sara Buten, MD.^{1,4}, Rohan Taylor, MD.^{1,5}, James Goldstein, MD.⁶, Cristal
- 7 Oxley,MD.⁷, Dusan Hadzi-Pavlovic, BSC.¹, Prof Colleen K. Loo, MD.^{1,2,8}
- 8 ¹ School of Psychiatry, University of New South Wales, Sydney, Australia
- 9 ² Black Dog Institute, Sydney, Australia

4

- 10 ³ Mental Health Department, Parc Taulí University Hospital, Institut d'Investigació I
- 11 Innovació Sanitària Parc Taulí (I3PT), Barcelona, Spain
- ⁴ Prince of Wales Hospital, Sydney, Australia
- ⁵ Concord Centre for Mental Health, Concord, Australia
- ⁶ Currumbin Clinic, Currumbin, Australia
- ⁷ Department of Child and Adolescent Psychiatry, Michael Rutter Centre South London and
- 16 Maudsley NHS Foundation Trust, UK
- 17 ⁸ St. George Hospital, Sydney, Australia

18 *Corresponding Author

- 19 Email. <u>stevan.nikolin@unsw.edu.au</u>
- 20 Address: Black Dog Institute, Hospital Road, Randwick 2031 NSW, Australia
- 21 Phone: +61 2 9385 8513
- 22 Funding
- 23 NHMRC project grant APP1051423

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 Abstract

25 Background

26 Transcranial electrical stimulation has broad potential as a treatment for depression.

27 Transcranial random noise stimulation (tRNS), which delivers randomly fluctuating current

28 intensities, may have greater cortical excitatory effects compared to other forms of

29 transcranial electrical stimulation. We therefore aimed to investigate the antidepressant

30 efficacy of tRNS.

31 Methods

Depressed participants were randomly assigned by computer number generator to receive 20 sessions of either active or sham tRNS over four weeks in a double-blinded, parallel group randomized-controlled trial. tRNS was delivered for 30mins with a direct current offset of 2mA and a random noise range of 2mA. Primary analyses assessed changes in depression severity using the Montgomery-Asperg Depression Rating Scale (MADRS). Neuroplasticity, neuropsychological, and safety outcomes were analysed as secondary measures.

38 Results

39 69 participants were randomised, of which three discontinued treatment early leaving 66

40 (sham n = 34, active n = 32) for per-protocol analysis. Depression severity scores reduced in

both groups (MADRS reduction in sham = 7.0 [95%CI 5.0-8.9]; and active = 5.2 [95%CI

42 3.2-7.3]). However, there were no differences between active and sham groups in the

43 reduction of depressive symptoms, or the number of participants meeting response (sham =

44 14.7%; active = 3.1%) and remission criteria (sham = 5.9%; active = 0%). Erythema,

45 paraesthesia, fatigue, and dizziness/light-headedness occurred more frequently in the active

46 tRNS group. Neuroplasticity, neuropsychological and acute cognitive effects were

47 comparable between groups.

48 **Conclusion**

- 49 Our results do not support the use of tRNS with the current stimulation parameters as a
- 50 therapeutic intervention for the treatment of depression.
- 51 Clinical trial registration at clinicaltrials.gov/NCT01792414.

52

53 Significance Statement

54 This is the first randomized sham-controlled clinical trial of a four-week course of 55 transcranial random noise stimulation (tRNS) for the treatment of depression. tRNS is a 56 relatively novel form of non-invasive electrical stimulation that uses mild, randomly fluctuating currents to constrain homeostatic mechanisms and increase brain excitability. We 57 58 investigated effects across multiple validated mood outcomes and comprehensively assessed 59 cognitive, neurophysiological, and physical side effects to examine the safety of tRNS. We 60 found no differences between active and sham conditions for all mood outcomes, and are thus 61 unable to lend support for tRNS as an effective treatment for depression. We found tRNS to be well-tolerated with no adverse acute cognitive, neuropsychological or severe physical side 62 63 effects, suggesting a course of 20 repeated sessions can be delivered safely.

64 Introduction

65 Although there are a number of established treatments for depression, a sizeable proportion of patients still fail to adequately respond, with a conservative estimate of 66 67 approximately one-third of these not reaching remission even after four trials of different antidepressant medication classes (A J Rush et al., 2006b). In addition, many patients fail to 68 69 complete a course of antidepressants due to side effects (A John Rush et al., 2006a; Trivedi et 70 al., 2006). While electroconvulsive therapy (ECT) remains the most effective treatment, with 71 response rates of up to 70% (Hag et al., 2015), treatment uptake and adherence can be limited 72 by patient concerns over possible cognitive side effects and the need for general anaesthetic. 73 Thus, there has been interest in the development of novel, non-convulsive brain stimulation 74 techniques that are well-tolerated and have a benign side effect profile, such as transcranial 75 electrical stimulation. These neuromodulatory techniques could have the greatest potential for 76 translation into widespread clinical use, being relatively inexpensive, easy to use, portable, 77 and safe (Bikson et al., 2016; Nikolin et al., 2018). Here we report an investigation of the 78 efficacy of one such technique, transcranial random noise stimulation (tRNS), for the 79 treatment of depression.

80 Transcranial electrical stimulation involves applying a weak electrical current to 81 cerebral tissue via scalp electrodes, resulting in modulation of neuronal membrane potentials 82 and spontaneous firing rates (M. A. Nitsche et al., 2008) that can lead to long term changes in cortical excitability and plasticity (Michael Nitsche and Paulus, 2001; Michael J Player et al., 83 84 2014). Applying a direct current between the electrodes, referred to as transcranial direct 85 current stimulation (tDCS), has been demonstrated to have antidepressant effects in clinical 86 trials (Colleen K Loo et al., 2012; Andre R Brunoni et al., 2013a; Andre R Brunoni et al., 87 2017). Recent meta-analyses of randomised, sham-controlled trials have found tDCS to be

88 more effective than sham stimulation, with significantly higher remission and response rates 89 as well as a greater reduction in depressive symptoms (André R. Brunoni et al., 2016; Mutz et al., 2018). As depression has increasingly been conceptualised as a disorder underpinned by 90 91 disrupted neuroplasticity (Pittenger and Duman, 2008; Liu et al., 2017), cumulative changes 92 to synaptic functioning may underlie the therapeutic effects observed in clinical trials of 93 tDCS (Szymkowicz et al., 2016). Modifying stimulation parameters to enhance cortical 94 excitability effects may therefore present a pathway to increase treatment efficacy. 95 tRNS is a more recently developed transcranial electrical stimulation technique that 96 involves randomly fluctuating current intensities over a broad frequency spectrum (between 97 0.1 to 640 Hz). There is some evidence that tRNS has comparable, if not greater, cortical 98 excitatory effects as compared to tDCS (Moliadze et al., 2014b; Ho et al., 2015; Inukai et al., 99 2016b). A single session of 10 minutes of 1 milliampere (mA) tRNS to the motor cortex has 100 been found to produce a greater increase in cortical excitability than tDCS, lasting up to 60 101 minutes beyond the stimulation period (Moliadze et al., 2014a; Inukai et al., 2016a), although 102 tDCS may lead to a longer period of excitation of at least 90 minutes post-stimulation 103 (Moliadze et al., 2014a). tRNS may also be applied with a direct current offset so that the 104 stimulation incorporates neuromodulatory features of tDCS, in addition to limiting 105 homeostatic responses via randomly fluctuating current intensities. Results from Ho et al. 106 (2015) suggest that tRNS with a direct current offset may be more effective in increasing 107 motor cortical excitability than the more common application of tRNS without an offset. 108 There has been a burgeoning growth in recent years of studies investigating the 109 application of tRNS to enhance sensory processing (Ghin et al., 2018; K. S. Rufener et al., 110 2018; Contemori et al., 2019), motor performance (Abe et al., 2019; Jooss et al., 2019), and 111 cognition (Snowball et al., 2013; Popescu et al., 2016; Mammarella et al., 2017; Shalev et al., 112 2018; Tyler et al., 2018) in healthy participants with largely promising results. To date,

113 however, few studies have examined the effectiveness of tRNS for clinical/therapeutic uses, 114 with such studies typically characterised by small sample sizes and/or varying efficacy (Chan 115 et al., 2012; Haesebaert et al., 2014; U. Palm et al., 2016; Hayward et al., 2017; Kreuzer et 116 al., 2017; Salemi et al., 2019). Regarding the effects of tRNS on mood, there is currently only 117 one report involving treatment of major depressive disorder (MDD). Chan et al. (2012) 118 reported a case of a patient diagnosed with MDD who had responded to two trials of tDCS (2 119 mA, 20 minutes, 15 sessions over 3 weeks) prior to trialling a 4-week course of open-label 120 tRNS (2 mA range with 1 mA direct current offset, 20 sessions lasting 20 minutes each). It was found that by the 15th session, there was a 63% reduction from baseline in the severity of 121 122 depressive symptoms, compared with a reduction of 31% and 25% at the end of the acute 123 treatment phase in the two prior trials of tDCS. For all three trials, depression scores at 124 baseline were similar but the patient reported faster improvement with tRNS and lesser skin 125 sensations compared to tDCS. Given this encouraging case report finding, and the potential 126 theoretical advantages of tRNS relative to tDCS, further investigation of the antidepressant 127 effects of tRNS is warranted.

128 The primary aim of this study, therefore, was to conduct the first randomised, sham-129 controlled trial of tRNS in depression. It was hypothesised that tRNS would have significant 130 antidepressant efficacy compared with a sham control over a 4-week treatment phase. A 131 secondary aim of this study was to examine whether antidepressant effects of tRNS were 132 mediated by restoration of brain neuroplasticity. We hypothesised that antidepressant 133 response to tRNS would be associated with increased brain plasticity, given prior findings of 134 reduced neuroplasticity in depressed individuals compared to healthy matched controls 135 (Michael J Player et al., 2013), and findings suggesting a normalisation of neuroplasticity 136 following antidepressant treatment using tDCS (Michael J Player et al., 2014). Lastly, as this 137 is the first treatment trial of tRNS for depression, a comprehensive neuropsychological test

138	battery was designed specifically to be sensitive to symptom changes, measure any adverse
139	cognitive effects, and to assess any potential acute cognitive enhancing effects.

140 Materials and Methods

141 Trial design

The main study phase used a double-blinded, parallel, randomized, sham-controlled 142 143 design. Participants were assigned by a computer-generated random number sequence to one of two groups: active tRNS or sham tRNS. Randomization was stratified according to 144 145 whether participants were diagnosed with unipolar or bipolar depression. Participants were 146 required to attend a total of 20 tRNS sessions over four weeks conducted on consecutive 147 weekdays during the sham-controlled phase. Participants who missed five or more sessions 148 during the sham-controlled phase were withdrawn from the trial, and were excluded from 149 analyses using a per-protocol approach. All participants were offered an additional 20 150 sessions of open-label active tRNS over four weeks, also administered every weekday. After 151 treatment in the acute daily treatment phases, participants entered a taper phase during which 152 they received once weekly tRNS treatment for four weeks with the final taper session 153 coinciding with a 1-month follow-up visit. Participants were then followed up at 3, 6 and 9 154 months. Participants and raters were blinded to tRNS condition and blinding was maintained 155 until the study was completed and the dataset locked.

Mood, neuroplasticity, and neuropsychological function were assessed at the intervals shown in Supplementary Table S1. Adequacy of blinding to treatment was assessed at the end of the sham-controlled phase by asking participants and raters to guess the tRNS condition administered during the first four weeks of treatment. To investigate whether treatment expectations may be a predictor of response, participants completed the Treatment

161 Expectancy Questionnaire (TEQ; see Supplementary Figure S1) at baseline before the first
162 tRNS session.

The study was powered for the primary aim of testing efficacy over the sham-163 164 controlled phase. From pilot data, it was assumed that tRNS would be at least as effective as 165 tDCS when tested in a sham-controlled trial, given that sampling criteria were very similar. 166 Means and standard deviations of the active and sham treatment groups from our previous, 167 sham-controlled, 3-week trial of tDCS (Colleen K Loo et al., 2012) were used, with 168 outcomes extrapolated for a 4-week comparison period. This resulted in an effect size of 169 Cohen's d = 0.7. For 80% power and $\alpha = 0.05$, a sample of 33 subjects per group was 170 required to demonstrate a difference between active and sham treatment. 171

172 Participants

173 At study entry, participants were at least 18 years old; in a current major depressive 174 episode (as part of a MDD or Bipolar Disorder) of a minimum four weeks duration, defined 175 according to Diagnostic and Statistical Manual of Mental Disorders (fourth edition, text 176 revision; DSM-IV-TR) criteria and established using the Mini International Neuropsychiatric 177 Interview (MINI; Version 5.0.0) (Sheehan et al., 1998) and study clinician assessment; and 178 had a total score of at least 20 on the Montgomery-Asberg Depression Rating Scale 179 (MADRS) (Montgomery and Asberg, 1979). Participants were free of antidepressant 180 medications, or continued on stable doses of antidepressant medications to which they had 181 failed to respond after an adequate course of treatment, with dosage unchanged for at least 182 four weeks prior to study entry. Bipolar participants were required to be on a mood stabilizer 183 medication (e.g. lithium, valproate, or carbamazepine) as prophylaxis against treatment-184 emergent mania or hypomania for the duration of the study.

185	Exclusion criteria included: psychotic disorder as per DSM-IV-TR; drug or alcohol
186	abuse or dependence within 12 months of study entry; inadequate response to ECT in the
187	current depressive episode; current benzodiazepine medication; rapid clinical response
188	required (e.g., due to high suicide risk); clinically defined neurological disorder or insult;
189	metal in the cranium; skull defects; skin lesions on the scalp at electrode sites; or pregnancy.
190	The study was approved by the human research ethics committee of the University of
191	New South Wales and was conducted at the Black Dog Institute in Sydney, Australia.
192	Participants provided written informed consent for this study. Recruitment began in January
193	2013 and the last follow-up was conducted in 2017. The study was registered with the
194	ClinicalTrials.gov website (Identifier: NCT01792414).
195	
196	Transcranial random noise stimulation
197	A DC-Stimulator Plus device (NeuroConn GmbH, Germany) applied high frequency
198	tRNS (100-640 Hz) via two 7 x 5 cm saline-soaked sponge-covered electrodes held in
199	position by a headband. Active tRNS was administered for 30 mins per session with a range
200	of 2 mA and an offset of 2 mA. The anode was placed over F3 (as per the 10-20 international
201	electroencephalogram system), corresponding to the left dorsolateral prefrontal cortex
202	(LDLPFC), and the cathode over F8. For sham stimulation, the current was ramped up over
203	10 s, left on for 30 s, then gradually ramped down over 10 s, so that both treatment groups
204	experienced an initial tingling sensation. The tRNS machine was then left on until the end of
205	the session to preserve blinding. This sham procedure resulted in adequate blinding for tDCS
206	in previous trials (e.g., (C. K. Loo et al., 2010; Colleen K Loo et al., 2012)), and was
207	therefore expected to be sufficient for tRNS, which produces milder skin sensations
208	compared to tDCS (Ambrus et al., 2010). Participants were comfortably seated at rest and did
209	not engage in any particular tasks during stimulation.

2	1	Ω
7	T	υ

211 Clinical outcome measures

212	The primary outcome measure for comparing active and sham tRNS was the MADRS,
213	which was administered by trained raters with established inter-rater reliability (intraclass
214	correlation coefficient > 0.7). Secondary measures were the Clinician Global Impression –
215	Improvement (CGI-I) (Guy, 1976), Beck Depression Inventory (BDI-II) (Beck et al., 1996) and
216	Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form (Q-LES-SF)
217	(Endicott et al., 1993) scales.
218	
219	Neuroplasticity outcome measures
220	As an optional study offered to participants in the main tRNS trial, a paired
221	associative stimulation (PAS) paradigm previously described in M. J. Player et al. (2012) was
222	used to assess the effects of tRNS on neuroplasticity. The PAS testing was conducted at
223	baseline before the first tRNS session, and again after completion of the sham-controlled and
224	open-label phases. Briefly, the PAS paradigm involves measuring motor evoked potentials
225	(MEPs) following single-pulse transcranial magnetic stimulation (TMS) via
226	electromyography (EMG) before and after applying a stimulation protocol (i.e., PAS) to the
227	motor cortex to assess changes in motor cortical excitability (see the Supplementary Material
228	for a detailed description of PAS methodology).
229	
230	Neuropsychological outcome measures
231	The following neuropsychological battery was administered to comprehensively
232	assess cognitive function: California Verbal Learning Test-II (CVLT-II) (Delis et al., 2000) -
233	verbal learning and memory; Ruff 2 & 7 (Ruff and Allen, 1996) – attention processes;
234	Wechsler Adult Intelligence Scale-IV edition (WAIS-IV) Digit Span subtest (Wechsler,

235 2008) – simple auditory attention and working memory; Symbol Digit Modality Test 236 (SDMT) (Smith, 1991) – psychomotor processing speed; Delis-Kaplan Executive Function 237 System (D-KEFS) Verbal Fluency test (Delis et al., 2001) – phonemic fluency, semantic 238 fluency, cognitive flexibility; and Cognitive Failures Ouestionnaire (Broadbent et al., 1982) – 239 subjective cognitive functioning. Alternative versions of the CVLT-II, D-KEFS Verbal 240 Fluency, and SDMT were used to minimize practice effects. In addition, computer 241 administered cognitive tests were used to assess safety and acute effects. A simple reaction 242 time test, in which participants were instructed to press a space bar as soon as they saw a 243 cross appear in the middle of a computer screen, was administered immediately before and 244 after the first tRNS session. An Emotion Recognition Task (Montagne et al., 2007), which 245 assessed recognition of six basic facial emotions, was also administered after the first tRNS 246 session.

247

248 Physical adverse events

As an additional safety outcome measure, physical adverse events were assessed each session using a tRNS Side Effects Questionnaire (Supplementary Figure S2), adapted from Andre Russowsky Brunoni et al. (2011), which collected information regarding the type of adverse event, its severity, and its causality.

253

254 Statistical Analyses

All statistical analyses were conducted using SPSS software (IBM SPSS Statistics 25 for Windows; SPSS Inc.). Outcome measures were analysed for change over the shamcontrolled phase using a mixed-effects repeated measures (MERM) model with a restricted number of covariates. Time was entered as a repeated measures factor with an unstructured covariance matrix, tRNS Condition (active or sham) was a between-subjects factor, and

260 subjects were included as a random effect. For mood and quality of life outcomes, covariates 261 were selected based on prior reports of their significant effect on antidepressant response to transcranial electrical stimulation; these included treatment resistance (Bikson et al., 2016) 262 263 (assessed by the Maudsley Staging Method (Fekadu et al., 2009)), and presence of concurrent 264 antidepressant medications e.g. selective-serotonin reuptake inhibitors, serotoninnorepinephrine reuptake inhibitors (A. R. Brunoni et al., 2013b; Andre R Brunoni et al., 265 266 2013a). A MERM model was similarly used for neuropsychological outcomes, with MADRS 267 mood scores at the respective time points included as a covariate. Acute cognitive effects 268 following the first session were examined using a two-way repeated measure analysis of 269 variance (RMANOVA), with factors of tRNS Condition and Time (pre and post session 1). 270 For the Emotion Recognition Task, a multivariate ANOVA (MANOVA) was conducted with 271 the between-subject factor of tRNS Condition. 272 Additional MERM analyses were conducted for the primary outcome measure 273 (MADRS). Baseline scores on the TEQ were added as a covariate to the MERM analysis to 274 test whether treatment expectations modified mood outcomes. To assess whether medication 275 use affected outcomes, each medication class (antidepressants, benzodiazepines, 276 antipsychotics, lithium and anticonvulsants) was entered as the only covariate in separate MERM analyses. 277 278 The number of responders (defined as a reduction in MADRS total score of $\geq 50\%$ 279 from baseline) and remitters (defined as a final MADRS total score < 10) at the end of the 280 sham-controlled phase were compared between active and sham tRNS groups using a 281 Fisher's exact test. 282 The association between participant or rater guesses (active or sham) and the

283 participant's assigned tRNS condition (active or sham) was tested using a Pearson Chi-square

- test with Yates' continuity correction. Cohen's kappa statistic was used to assess agreement
- 285 between participant and rater guesses.
- 286 Statistical tests were two-tailed and significance was set at p < 0.05.

287 **Results**

- 288 A total of 69 participants met inclusion criteria and were randomized to receive either active
- 289 or sham tRNS during the sham-controlled phase (see the CONSORT flow diagram,
- 290 Supplementary Figure S3). A total of 66 participants (sham: 34, active: 32) completed the
- sham-controlled phase and were analysed using a per-protocol approach. Table 1 shows
- 292 demographic and clinical characteristics for active and sham tRNS groups at baseline.

	Sham	Active
n	34	32
Medications (yes/no)		
Any concurrent medication	27/7	22/10
Antidepressant	23/11	20/12
Lithium	1/33	2/30
Benzodiazepine*	2/32	2/30
Antipsychotic	6/28	4/28
Anticonvulsant	5/29	1/31
Clincial and demographic variables (m, SD)		
Gender (m/f)	19/15	17/15
Melancholic (yes/no)	19/9	12/12
MDD/BP1/BP2	30/3/1	30/0/2
Age (years)	48.8 (12.3)	47.5 (12.0)
Age at onset (years)	27.0 (9.6)	27.5 (9.6)
Duration of current episode (months)	24.4 (32.2)	37.2 (48.0)
Duration of previous episodes (months)	65.9 (65.8)	88.5 (93.6)
Antidepressants failed current episode	2.1 (1.7)	2.6 (2.9)
Total lifetime failed antidepressants	4.0 (3.0)	5.0 (5.1)
Maudsley Staging score	7.3 (2.1)	6.5 (1.9)
Baseline MADRS score	29.5 (4.6)	30.1 (5.0)
Baseline BDI-II score	33.8 (9.1)	34.1 (9.4)
Baseline CGI-S score	4.4 (0.6)	4.4 (0.6)
Baseline Q-LES-SF score	32.8 (10.5)	34.9 (11.2)
Baseline TEQ score	24.5 (7.6)	24.1 (7.1)

293 Table 1. Comparison of demographic and clinical characteristics at baseline.

²⁹⁴ *Participants were required to cease benzodiazepine medication use prior to commencing the trial.

MDD: Major depressive disorder. BP1/BP2: Bipolar I and bipolar II disorder. MADRS: Montgomery-Asberg Depression
 Rating Scale. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. BDI-II: Beck Depression
 Inventory. CGI-S: Clinician Global Impression Severity scale, is a 7-point clinician-rated scale ranked from 1-normal to 7 extremely ill. TEQ: Treatment Expectancy Questionnaire.

300 Clinical outcome measures

- 301 Table 2 shows the results for all MERM analyses of mood and quality of life outcome
- 302 measures during the sham-controlled phase using per-protocol and intention-to-treat
- 303 approaches in accordance with CONSORT guidelines for parallel group randomised control
- 304 trials (Schulz et al., 2010). MERM analysis of MADRS scores showed a significant effect of
- Time (p < 0.001). There was, however, no effect of tRNS Condition (p = 0.630), and no
- 306 significant Time \times Condition interaction (p = 0.445; see Figure 1). Repeating the analysis

307 while incorporating scores from the Treatment Expectations Questionnaire as an additional 308 covariate did not modify outcomes. Concurrent medications did not significantly affect 309 outcomes when entered as covariates in separate MERM analyses (see Supplementary Table 310 S2). Supplementary Table S3 shows results from MERM analyses of all outcome measures 311 acquired during the acute daily treatment phases combined (i.e. both sham-controlled and 312 open-label phases). Supplementary Figure S4 shows graphs of mood and quality of life 313 measures for all time-points up to the 9-month follow-up assessment. 314 One participant in the active tRNS group (3.1%), and five participants receiving sham 315 tRNS (14.7%), were considered treatment responders after completion of the sham-controlled 316 phase (i.e. following 20 sessions of tRNS). Only two participants met the remission criterion, 317 both in the sham tRNS condition (5.9%). Fisher's exact tests revealed no statistically

318 significant differences between active and sham tRNS conditions for response (p = 0.198)

and remission (p = 0.493) rates.




Figure 1. Mood scores. Graph showing MADRS scores (estimated marginal means ±
SD) across rating time points, including the sham-controlled phase (from baseline to 4weeks), open-label phase (from 4 – 8 weeks), and 1-month follow-up assessment following

- 324 the final taper session. Dotted lines indicate sham tRNS sessions delivered during the sham-
- 325 controlled phase.

Table 2. Mood and quality of life outcome measures. Estimated marginal means and results from MERM analyses during the shamcontrolled phase. MERM analyses were performed including the following covariates: Maudsley staging method total score as a measure of

	Base	Baseline		Week 2		Week 4		Condition		Time		Time × Condition	
Mood Assessments - mean (n, SEM)	Sham	Active	Sham	Active	Sham	Active	F	р	F	р	F	р	
Per-protocol analysis													
MADRS	29.1 (33, 0.8)	28.9 (32, 0.8)	24.4 (33, 1.0)	24.8 (32, 1.1)	22.1 (34, 1.2)	23.7 (32, 1.3)	0.24	0.630	41.73	<0.001	0.82	0.445	
BDI-II	32.6 (31, 1.7)	33.2 (28, 1.8)	25.2 (34, 1.9)	27.2 (32, 2.0)	22.1 (32, 1.9)	24.9 (31, 2.0)	0.72	0.399	24.56	<0.001	0.46	0.762	
CGI-I	-	-	3.5 (33, 0.1)	3.6 (32, 0.1)	3.1 (33, 0.1)	3.4 (32, 0.1)	2.24	0.140	12.69	<0.001	2.10	0.153	
Q-LES-SF	32.4 (34, 1.9)	36.0 (30, 2.1)	-	-	43.5 (32, 2.8)	43.9 (31, 2.9)	0.45	0.503	31.67	<0.001	0.84	0.362	
Intention-to-treat analysis													
MADRS	29.1 (34, 0.8)	29.0 (34, 0.8)	24.4 (33, 1.0)	24.8 (34, 1.1)	22.1 (34, 1.2)	23.7 (32 1.3)	0.29	0.593	43.09	<0.001	0.77	0.467	
BDI-II	32.4 (32, 1.6)	33.4 (30, 1.7)	24.9 (34, 1.9)	27.1 (34, 2.0)	21.9 (32, 1.9)	25.1 (31, 2.0)	1.07	0.306	25.07	<0.001	0.58	0.678	
CGI-I	-	-	3.5 (33, 0.1)	3.6 (34, 0.1)	3.1 (33, 0.1)	3.4 (32, 0.1)	2.60	0.112	13.07	<0.001	1.98	0.165	
Q-LES-SF	32.5 (35, 1.8)	35.8 (32, 2.0)	-	-	43.6 (32, 2.8)	43.8 (31, 2.9)	0.37	0.545	32.00	<0.001	0.80	0.376	

328 treatment resistance, and antidepressant use. Statistically significant p-values (<0.05) are highlighted in bold.

329 MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-I: Clinician Global Impression Improvement scale, is a 7-point clinician-rated scale ranked 330 from 1-very much improved to 7-very much worse. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. m: Mean. SEM: Standard error of measure.

331 Neuroplasticity outcome measures

332	A total of 44 participants (sham: 25, active: 19) completed the optional PAS study to
333	assess changes in motor cortical excitability. A MERM analysis found no significant effects
334	of Time ($p = 0.209$) or Condition ($p = 0.780$), and no significant Time × Condition interaction
335	($p = 0.570$; see Table 3, and Supplementary Figure S5). Furthermore, change in MADRS
336	scores did not correlate with changes in MEP amplitudes from baseline to the end of the
337	sham-controlled phase (r = -0.02, $p = 0.905$; Supplementary Figure S6). Results from
338	intention-to-treat analyses are also reported in Supplementary Table S4.
339	
340	Neuropsychological outcomes
341	Neuropsychological outcomes during the sham-controlled phase are shown in Table 3. There
342	were no significant main effects of Time, and no significant Time \times Condition interaction

343 effects for all neuropsychological measures. Results from intention-to-treat analyses are also

344	reported	in Sup	oplement	ary Ta	ble S4.

345 Table 3. Neuroplasticity and neuropsychological outcome measures. Estimated marginal means and results from MERM analyses346 during the sham-controlled phase. The neuroplasticity MERM analysis were performed including the following covariates: Maudsley staging347 parameters total score as a measure of treatment resistance, and antidepressant use. Neuropsychological MERM analyses were performed using348 MADRS scores as a covariate. Statistically significant p-values (<0.05) are highlighted in bold.</p>

	Baseline		We	Condition		Time		Time × Condition		
	Sham	Active	Sham	Active	F	р	F	р	F	р
Neuroplasticity Assessment (m, SEM)										
PAS: MEP amplitude	1.24 (0.10)	1.21 (0.12)	1.31 (0.09)	1.40 (0.10)	0.08	0.780	1.63	0.209	0.33	0.570
Neuropsychological Assessments (m, SEM)										
CVLT-II: Trial 1-5 total recall t-score	45.7 (2.8)	48.7 (2.2)	46.3 (2.3)	49.7 (2.2)	2.12	0.148	0.12	0.734	0.01	0.913
CVLT-II: Long delay free recall z-score	-0.41 (0.21)	0.03 (0.22)	-0.64 (0.22)	-0.38 (0.21)	2.69	0.104	1.85	0.176	0.20	0.653
D-KEFS: Letter fluency scaled score	11.2 (0.7)	11.5 (0.7)	10.9 (0.7)	11.9 (0.7)	0.97	0.327	0.01	0.945	0.32	0.575
D-KEFS: Category fluency scaled score	10.3 (0.8)	10.9 (0.8)	9.8 (0.8)	11.8 (0.8)	2.84	0.094	0.05	0.828	0.80	0.372
D-KEFS: Category switching total scaled score	10.0 (0.6)	11.1 (0.6)	9.6 (0.6)	10.6 (0.6)	3.36	0.069	0.50	0.480	0.02	0.888
Ruff 2 & 7: Total speed t-score	47.4 (1.9)	49.9 (1.9)	51.3 (1.9)	53.6 (1.8)	1.66	0.200	3.45	0.066	0.01	0.946
Ruff 2 & 7: Total accuracy t-score	49.6 (2.3)	46.6 (2.4)	50.4 (2.4)	48.7 (2.3)	1.02	0.316	0.34	0.561	0.08	0.779
SDMT: Total correct z-score	-0.31 (0.18)	0.25 (0.18)	-0.02 (0.19)	0.41 (0.18)	7.78	0.006	1.32	0.254	0.15	0.703
WAIS-IV Digit Span: Total correct scaled score	9.7 (0.5)	11.5 (0.6)	10.5 (0.6)	12.6 (0.5)	13.00	<0.001	2.57	0.112	0.12	0.732
CFQ: Total score	50.0 (2.2)	46.8 (2.3)	49.9 (2.3)	50.0 (2.2)	0.52	0.474	0.40	0.528	0.57	0.451

PAS: Paired associative stimulation. MEP: motor evoked potential. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult Intelligence Scale. SDMT: Symbol Digit Modalities Test.

350 D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire. m: Mean. SEM: Standard error of measure.

351 Acute cognitive effects

For reaction time, the main effects of Time (p = 0.404), Condition (p = 0.992), and the Time × Condition interaction effect (p = 0.949) were not statistically significant. Further, for the Emotion Recognition Task the main effect of tRNS Condition was not statistically significant (p = 0.347).

356 Physical adverse events

357 Adverse events occurring during the sham-controlled and open-label phases of the

- trial are presented in Table 4. Side-effects were transient and mild-to-moderate in severity.
- 359 Pearson Chi-square tests revealed significantly more instances of erythema (skin redness; p <
- 360 0.001), paraesthesia (tingling, burning, and itching sensations; p < 0.001), fatigue (p = 0.006),
- and dizziness/light-headedness (p = 0.002) following active tRNS as compared to sham tRNS
- 362 sessions.

Table 4. Physical adverse event frequency. Adverse events are sorted according to
overall likelihood of occurrence, with events most likely to occur listed first. Differences in
frequency of adverse event occurrence during the sham-controlled phase was tested using
Pearson Chi-square tests with Yates' continuity correction. Statistically significant p-values
(<0.05) are highlighted in bold.

				Open-label phase				
	Sham (646 sessions)		Active (650 sessions)		Pearson	Chi-square		ctive sessions)
	n	%	'n	%	χ2	<i>p</i> -value	n	%
Erythema	129	20.0	454	69.8	323.67	<0.001	781	67.3
Tingling	126	19.5	332	51.1	139.96	<0.001	623	53.7
Burning	15	2.3	251	38.6	214.14	<0.001	370	31.9
Itching	40	6.2	97	14.9	25.21	<0.001	170	14.6
Fatigue	33	5.1	60	9.2	7.66	0.006	75	6.5
Headache	43	6.7	30	4.6	2.17	0.141	31	2.7
Dizziness/light-headedness	10	1.5	31	4.8	9.95	0.002	48	4.1
Nausea	7	1.1	15	2.3	2.22	0.136	36	3.1
Scalp Discomfort	7	1.1	9	1.4	0.06	0.811	10	0.9
Other	14	2.2	26	4.0	3.05	0.081	58	5.0

368

369 Blinding integrity

370 Participants were asked to guess their treatment condition at the end of the double-371 blinded sham-controlled phase. 75% of participants in the sham condition correctly guessed 372 they received sham tRNS, and 55% of participants in the active condition correctly guessed 373 they had received active tRNS. A Pearson Chi-square test of participant guesses was significant ($\gamma^2 = 4.68$; p = 0.031), suggesting that participants were not adequately blinded to 374 their treatment condition. To determine whether participant guesses of treatment condition 375 376 may have influenced mood outcomes, we performed a post-hoc simple linear regression 377 analysis; percent change in MADRS score over the 4-week sham-controlled phase was 378 selected as the dependent variable, and participant guess (active, sham) as the independent variable. This analysis was not statistically significant ($R^2 = 0.023$, F = 1.43, p = 0.237). 379

- 380 Blinded study raters were similarly asked to guess participants' treatment condition at
- the end of the sham-controlled phase. Raters correctly guessed that participants had received
- 382 sham tRNS 56% of the time, and active tRNS 31% of the time. A Pearson Chi-square test
- found this difference not to be statistically significant ($\chi^2 = 0.492$; p = 0.483). Furthermore,
- 384 Cohen's kappa showed no agreement between participant and rater guesses ($\kappa = 0.134$; p =
- 385 0.329).

386 **Discussion**

387 Here we report the results of the first randomized control trial to examine the efficacy 388 of tRNS for the treatment of depression. Although there was a significant reduction of 389 depressive symptoms over the duration of the study period, there was no difference in the rate of improvement between sham and active tRNS conditions. Further, there was no significant 390 391 effect of tRNS on neuroplasticity measures in the subset of participants that completed the 392 PAS paradigm, suggesting that stimulation did not increase global cortical excitability. tRNS 393 was found to be safe with no adverse acute cognitive, neuropsychological or severe physical side effects. However, tRNS resulted in a higher incidence rate of skin redness (erythema) 394 395 and paraesthesia (tingling, itching, and burning sensations) in the active condition, as well as 396 fatigue and dizziness/light-headedness, which occurred in fewer than 10% of sessions. 397 Nevertheless, the stimulation protocol was well-tolerated with only one participant dropping-398 out due to adverse effects, which were not conclusively associated with tRNS. 399 The results of this study do not support the use of tRNS with the current stimulation 400 parameters as a therapeutic intervention for the treatment of depression. Despite encouraging 401 initial evidence of significant reductions in depression scores in patients with fibromyalgia 402 (Curatolo et al., 2017), and a case report of improvement in MDD (Chan et al., 2012), mood 403 and quality of life outcomes in the active tRNS group were no different from the placebo-404 controlled response in the sham group at all time-points. The size of reductions in depressive 405 symptoms observed in both conditions of the present study is broadly similar to the sham 406 condition of previous trials of tDCS for depression (Blumberger et al., 2012; Colleen K Loo 407 et al., 2012; U Palm et al., 2012; Andre R Brunoni et al., 2013a; Bennabi et al., 2015; 408 Sampaio-Junior et al., 2018). Of these previous tDCS trials, our study design was most

- 409 similar to a recent international multisite investigation conducted by our group, which
- 410 observed improvements in depression scores of 27.8% and 22.3% in sham and active tDCS

411 conditions, respectively, as compared to 24.1% and 18.0% in sham and active tRNS 412 conditions (Colleen K Loo et al., 2018). We recruited participants using analogous 413 inclusion/exclusion criteria, participant demographic and clinical characteristics, and adopted 414 comparable stimulation parameters, at least in terms of treatment duration (30 minutes), 415 session number and frequency (20 daily weekday sessions), and direct current intensity (2 416 mA direct current offset in the present study vs a marginally stronger current intensity of 2.5 417 mA in the tDCS study). Interestingly, the present tRNS trial and Colleen K Loo et al. (2018) 418 have used the highest total number of sessions and strongest stimulation parameters, 419 including current intensity, compared to other investigations of the antidepressant effects of 420 transcranial electrical stimulation (Blumberger et al., 2012; Colleen K Loo et al., 2012; U 421 Palm et al., 2012; Andre R Brunoni et al., 2013a; Bennabi et al., 2015), with both studies 422 reporting no advantage of active stimulation over sham. Overall, studies show tDCS has 423 antidepressant efficacy (Mutz et al., 2018), though one study suggested this may be less than 424 escitalopram (Andre R Brunoni et al., 2017). 425 Another possible explanation for null findings in the present study is that the sample 426 was too severely ill to respond to tRNS treatment. On average, participants had failed 4-5 427 antidepressants and depression scores just below the cut-off for severe depression (MADRS 428 > 34; see Table 1). Research suggests that participants with treatment resistant depression do 429 not respond as well transcranial electrical stimulation, such as tDCS (Blumberger et al., 2012;

430 U Palm et al., 2012; Bennabi et al., 2015).

The synaptic plasticity hypothesis of depression purports that MDD is characterized by a partial reduction in long-term potentiation-like processes (Michael J Player et al., 2013; Kuhn et al., 2016), suggesting that impaired synaptic plasticity, particularly in the prefrontal cortex, is a key feature of the pathophysiology of depression (Goto et al., 2010; Duman et al., 2016; Noda et al., 2018). This hypothesis is supported by evidence that the therapeutic

436 efficacy of antidepressants is, at least partly, due to their capacity to increase neural plasticity 437 (Santarelli et al., 2003; Castrén and Hen, 2013). Similarly, prior work from our group has 438 demonstrated that a course of tDCS increases neuroplasticity and mood outcomes in 439 depression. However, a correlation between these measures could not be confirmed due to the 440 limited sample size (n = 18) (Michael J Player et al., 2014). Despite a larger sample size from 441 which to detect small effects of the intervention, we did not see an increase in neuroplasticity 442 levels following tRNS. Previous research has shown that tRNS can induce acute neuroplastic 443 after-effects, measured by investigating changes to motor cortex excitability using TMS 444 motor evoked potentials (Terney et al., 2008; Chaieb et al., 2015; Ho et al., 2015). However, 445 there is no evidence to date to suggest cumulative changes in neuroplasticity following a 446 course of multiple repeated sessions of tRNS, as assessed in this study. An important caveat 447 to our results is that only a subset of participants (44/69) completed the PAS study. It is 448 theoretically possible that the subset of participants who underwent the PAS protocol had 449 different clinical, physiological, or behavioural characteristics (e.g. greater levels of 450 motivation) and may thus not be representative of the larger sample. 451 The exact purported mechanisms of action for prolonged cortical excitation following 452 tRNS are unclear, but may include either 1) temporal summation of neural activity when 453 random noise stimuli and ongoing endogenous neuronal activity occur in close succession 454 (Fertonani et al., 2011), and/or 2) enhancement of neuronal signalling via the principle of 455 stochastic resonance (van der Groen and Wenderoth, 2017). The latter refers to signals that 456 are too weak to exceed a threshold being amplified by adding a random noise stumulus, 457 improving the signal-to-noise ratio and the synchronization and coherence of neuronal 458 networks (Moss et al., 2004; Pavan et al., 2019). Though more research is required to

determine which of these mechanisms dominates, the action of tRNS appears to rely heavily

460 on detection and propagation of weak ongoing endogenous neuronal signals. The notion of

461 stochastic resonance has been demonstrated in several tRNS experiments aimed at enhancing 462 sensitivity to sensory inputs, including visual, auditory, and tactile stimuli (van der Groen and Wenderoth, 2017). Interestingly, investigations of auditory (Katharina S Rufener et al., 2017) 463 464 and visual (Van der Groen et al., 2018) perceptual thresholds have shown that tRNS has its 465 largest effect on near-threshold stimuli, whereas stimuli clearly above and below threshold 466 were unaffected. It may be for this reason that the only positive randomized control trials 467 using tRNS in clinical populations have stimulated the sensory and motor cortices, 468 specifically in the treatment of tinnitus via the auditory cortex (Vanneste et al., 2013), or 469 stimulation of the motor cortex for chronic pain in fibromyalgia (Curatolo et al., 2017). tRNS 470 may restore the dysfunctional activity in these cortical structures by normalizing their 471 capacity to filter weak signals amidst background neural noise. In complex disorders such as depression, however, it is unclear what the depressed 'signal' might be. Studies seeking to 472 473 use tRNS for other complex disorders by stimulating prefrontal cortical regions have also 474 reported negative findings, i.e. for the treatment of multiple sclerosis (U. Palm et al., 2016), 475 and vegetative state (Mancuso et al., 2017). Similarly to depression, these illnesses do not 476 consist of a well-defined neural signal whose signalling properties can be augmented by 477 tRNS to revert pathophysiological dysfunctions of brain activity.

478 Although the present study reports null findings for the use of tRNS in depression, it 479 provides valuable information regarding the safety and tolerability of multiple repeated 480 sessions of tRNS. To the best of our knowledge, the previous longest delivery of tRNS was 481 15 sessions (Chan et al., 2012), whereas participants in the current study experienced up to 40 482 sessions over eight weeks if allocated to the active tRNS condition. Adverse events of 483 erythema and paraesthesia were reported more frequently in the active tRNS condition as 484 compared to sham. These results are comparable to those observed in the tDCS literature, in 485 which meta-analyses similarly suggest a greater frequency of erythema and paraesthesia

486 (Moffa et al., 2017; Nikolin et al., 2018). Of interest, fatigue and dizziness/light-headedness 487 were also noted more frequently during active tRNS sessions. These side effects are not a 488 common adverse effect of tDCS and might be unique to the tRNS stimulation parameters 489 used in the current study, for example, due to the current intensity ranging as high as 3 mA (2 490 mA direct offset with ±1 mA amplitude fluctuation). Importantly, fatigue and dizziness/light-491 headedness occurred rarely, in only 9.2% of sessions for fatigue, and 4.8% for light-492 headedness. Additionally, these adverse events were transient, resolved on their own shortly 493 after cessation of stimulation, and were not reported to be severe in intensity. 494 A limitation of the present study is that blinding was not preserved, possibly due to 495 the increased incidence of adverse events during active tRNS compared to sham. One would 496 expect inadequate blinding to reduce placebo effects for participants in the sham condition, 497 and potentially enhance them for participants receiving active tRNS, thereby increasing the 498 likelihood of observing a difference between groups. This was not the case in the present 499 study. Indeed, scores for mood outcomes were quantitatively (but not significantly) better in 500 the sham condition compared to active tRNS, suggesting that inadequate blinding did not bias 501 results in favour of the active treatment. Future studies may consider alternative methods to 502 adequately blind participants, including the use of a topical salve beneath the site of 503 stimulation to reduce paraesthetic effects and erythema (McFadden et al., 2011; Guarienti et 504 al., 2015), or comparisons against an active control condition (Fonteneau et al., 2019). 505 A major strength of the present study is the research design, which included double 506 blinding of participants and raters, examination of mood outcomes in addition to 507 neuroplasticity changes, comprehensive assessment of adverse events using 508 neuropsychological and physical measures, reporting of long-term follow-up outcomes up to 509 9-months following completion of the open-label phase, and rigorous statistical analysis 510 methodology informed by CONSORT guidelines.

511 **Conclusion**

512	This study represents the first randomised control trial for the use of tRNS to treat
513	depression. Our findings do not lend support for the use of tRNS as a therapeutic intervention
514	for depression. Antidepressant response was similar between active and sham tRNS
515	conditions. tRNS did not increase motor cortical excitability, a measure of neuroplasticity
516	associated with antidepressant response in other successful therapeutic clinical trials of
517	depression (Santarelli et al., 2003; Castrén and Hen, 2013). The profile of adverse events for
518	tRNS was similar to that of tDCS, with a significantly greater likelihood of erythema and
519	paraesthesia in the active tRNS condition, in addition to a higher incidence rate of fatigue and
520	dizziness/light-headedness. Participant blinding was not preserved and may be related to the
521	increased frequency of side effects in the active condition. Overall, the treatment was well-
522	tolerated by participants.

523

524 Funding

525 This study was funded by a National Health and Medical Research Council526 (NHMRC) Project Grant: APP1051423.

527

528 **Conflict of Interest**

529 CL has served on a Janssen Advisory Board for Janssen and received an honorarium 530 from Mecta for teaching at an international electroconvulsive therapy (ECT) course. The 531 remaining authors have no conflicts of interest to declare.

533 **References**

- Abe T, Miyaguchi S, Otsuru N, Onishi H (2019) The effect of transcranial random noise stimulation on corticospinal excitability and motor performance. Neurosci Lett 705:138-142.
- 536 Ambrus GG, Paulus W, Antal A (2010) Cutaneous perception thresholds of electrical stimulation
- 537 methods: comparison of tDCS and tRNS. Clin Neurophysiol 121:1908-1914.
- 538 Beck AT, Steer RA, Brown GK (1996) Manual for Beck Depression Inventory-II. San Antonio, TX: The 539 Psychological Corporation.
- 540 Bennabi D, Nicolier M, Monnin J, Tio G, Pazart L, Vandel P, Haffen E (2015) Pilot study of feasibility of
- 541 the effect of treatment with tDCS in patients suffering from treatment-resistant depression treated
- 542 with escitalopram. Clin Neurophysiol 126:1185-1189.
- 543 Bikson M et al. (2016) Safety of Transcranial Direct Current Stimulation: Evidence Based Update 544 2016. Brain Stimul 9:641-661.
- 545 Blumberger D, Tran L, Fitzgerald P, Hoy KB, Daskalakis ZJ (2012) A randomized double-blind sham-
- 546 controlled study of transcranial direct current stimulation for treatment-resistant major depression.547 Front Psychiatry 3:74.
- 548 Broadbent DE, Cooper PF, FitzGerald P, Parkes KR (1982) The Cognitive Failures Questionnaire (CFQ) 549 and its correlates. Br J Clin Psychol 21:1-16.
- 550 Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F (2011) A systematic review on
- reporting and assessment of adverse effects associated with transcranial direct current stimulation.
 Int J Neuropsychopharmacol 14:1133-1145.
- 553 Brunoni AR, Valiengo L, Baccaro A, Zanao TA, de Oliveira JF, Goulart A, Boggio PS, Lotufo PA,
- 554 Bensenor IM, Fregni F (2013a) The sertraline vs electrical current therapy for treating depression
- 555 clinical study: results from a factorial, randomized, controlled trial. JAMA Psychiatry 70:383-391.
- 556 Brunoni AR, Ferrucci R, Bortolomasi M, Scelzo E, Boggio PS, Fregni F, Dell'Osso B, Giacopuzzi M,
- 557 Altamura AC, Priori A (2013b) Interactions between transcranial direct current stimulation (tDCS)
- and pharmacological interventions in the Major Depressive Episode: findings from a naturalistic
- 559 study. Eur Psychiatry 28:356-361.
- 560 Brunoni AR, Moffa AH, Sampaio-Junior B, Borrione L, Moreno ML, Fernandes RA, Veronezi BP,
- 561 Nogueira BS, Aparicio LV, Razza LB (2017) Trial of electrical direct-current therapy versus
- 562 escitalopram for depression. N Engl J Med 376:2523-2533.
- 563 Brunoni AR, Moffa AH, Fregni F, Palm U, Padberg F, Blumberger DM, Daskalakis ZJ, Bennabi D,
- 564 Haffen E, Alonzo A, Loo CK (2016) Transcranial direct current stimulation for acute major depressive 565 episodes: meta-analysis of individual patient data. Br J Psychiatry 208:522-531.
- 566 Castrén E, Hen R (2013) Neuronal plasticity and antidepressant actions. Trends Neurosci 36:259-267.
- 567 Chaieb L, Antal A, Paulus W (2015) Transcranial random noise stimulation-induced plasticity is
- 568 NMDA-receptor independent but sodium-channel blocker and benzodiazepines sensitive. Front
 569 Neurosci 9:125-125.
- 570 Chan HN, Alonzo A, Martin DM, Player M, Mitchell PB, Sachdev P, Loo CK (2012) Treatment of major
- depressive disorder by transcranial random noise stimulation: case report of a novel treatment. BiolPsychiatry 72:e9-e10.
- 573 Contemori G, Trotter Y, Cottereau BR, Maniglia M (2019) tRNS boosts perceptual learning in
- 574 peripheral vision. Neuropsychologia 125:129-136.
- 575 Curatolo M, La GB, Cosentino G, Baschi R, Salemi G, Talotta R, Romano M, Triolo G, De MT, Fierro B
- 576 (2017) Motor cortex tRNS improves pain, affective and cognitive impairment in patients with
- fibromyalgia: preliminary results of a randomised sham-controlled trial. Clin Exp Rheumatol 35:100-105.
- 579 Delis DC, Kaplan E, Kramer JH (2001) Delis-Kaplan Executive Function System (D-KEFS). San Antonio, 580 TX: The Psychological Corporation.
- 581 Delis DC, Kramer JH, Kaplan E, Ober BA (2000) California Verbal Learning Test (2nd ed.). San Antonio,
- 582 TX: The Psychological Corporation.

- 583 Duman RS, Aghajanian GK, Sanacora G, Krystal JH (2016) Synaptic plasticity and depression: new
- insights from stress and rapid-acting antidepressants. Nat Med 22:238.
- 585 Endicott J, Nee J, Harrison W, Blumenthal R (1993) Quality of Life Enjoyment and Satisfaction
- 586 Questionnaire: a new measure. Psychopharmacol Bull 29:321-326.
- 587 Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, Cleare AJ (2009) A
- 588 multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method.
- 589 J Clin Psychiatry 70:177-184.
- 590 Fertonani A, Pirulli C, Miniussi C (2011) Random noise stimulation improves neuroplasticity in
- 591 perceptual learning. J Neurosci 31:15416-15423.
- 592 Fonteneau C, Mondino M, Arns M, Baeken C, Bikson M, Brunoni AR, Burke MJ, Neuvonen T, Padberg
- 593 F, Pascual-Leone A (2019) Sham tDCS: A hidden source of variability? Reflections for further blinded, 594 controlled trials. Brain Stimul.
- 595 Ghin F, Pavan A, Contillo A, Mather G (2018) The effects of high-frequency transcranial random noise
- stimulation (hf-tRNS) on global motion processing: An equivalent noise approach. Brain Stimul11:1263-1275.
- 598 Goto Y, Yang CR, Otani S (2010) Functional and dysfunctional synaptic plasticity in prefrontal cortex: 599 roles in psychiatric disorders. Biol Psychiatry 67:199-207.
- 600 Guarienti F, Caumo W, Shiozawa P, Cordeiro Q, Boggio PS, Benseñor IM, Lotufo PA, Bikson M,
- 601 Brunoni AR (2015) Reducing transcranial direct current stimulation-induced erythema with skin
- 602 pretreatment: considerations for sham-controlled clinical trials. Neuromodulation 18:261-265.
- 603 Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Rockville, MD.: U.S. Department
- 604 of Health, Education, and Welfare.
- Haesebaert F, Mondino M, Saoud M, Poulet E, Brunelin J (2014) Efficacy and safety of fronto-
- temporal transcranial random noise stimulation (tRNS) in drug-free patients with schizophrenia: acase study. Schizophr Res 159:251-252.
- 608 Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ (2015) Response of depression to
- 609 electroconvulsive therapy: a meta-analysis of clinical predictors. J Clin Psychiatry 76:1374-1384.
- 610 Hayward KS, Brauer SG, Ruddy KL, Lloyd D, Carson RG (2017) Repetitive reaching training combined
- 611 with transcranial Random Noise Stimulation in stroke survivors with chronic and severe arm paresis
- 612 is feasible: a pilot, triple-blind, randomised case series. J Neuroeng Rehabil 14:46.
- 613 Ho KA, Taylor JL, Loo CK (2015) Comparison of the effects of transcranial random noise stimulation
- and transcranial direct current stimulation on motor cortical excitability. J ect 31:67-72.
- 615 Inukai Y, Saito K, Sasaki R, Tsuiki S, Miyaguchi S, Kojima S, Masaki M, Otsuru N, Onishi H (2016a)
- 616 Comparison of Three Non-Invasive Transcranial Electrical Stimulation Methods for Increasing Cortical
- 617 Excitability. Frontiers in human neuroscience 10:668-668.
- 618 Inukai Y, Saito K, Sasaki R, Tsuiki S, Miyaguchi S, Kojima S, Masaki M, Otsuru N, Onishi H (2016b)
- 619 Comparison of Three Non-Invasive Transcranial Electrical Stimulation Methods for Increasing Cortical 620 Excitability. Front Hum Neurosci 10:668-668.
- 621 Jooss A, Haberbosch L, Kohn A, Ronnefarth M, Bathe-Peters R, Kozarzewski L, Fleischmann R, Scholz
- 622 M, Schmidt S, Brandt SA (2019) Motor Task-Dependent Dissociated Effects of Transcranial Random
- 623 Noise Stimulation in a Finger-Tapping Task Versus a Go/No-Go Task on Corticospinal Excitability and 624 Task Performance. Front Neurosci 13:161.
- 625 Kreuzer PM, Vielsmeier V, Poeppl TB, Langguth B (2017) A Case Report on Red Ear Syndrome with
- Tinnitus Successfully Treated with Transcranial Random Noise Stimulation. Pain Physician 20:E199 627 e205.
- 628 Kuhn M, Mainberger F, Feige B, Maier JG, Mall V, Jung NH, Reis J, Klöppel S, Normann C, Nissen C
- 629 (2016) State-dependent partial occlusion of cortical LTP-like plasticity in major depression.
- 630 Neuropsychopharmacol 41:1521.
- Liu W, Ge T, Leng Y, Pan Z, Fan J, Yang W, Cui R (2017) The Role of Neural Plasticity in Depression:
- 632 From Hippocampus to Prefrontal Cortex. Neural Plast 2017:6871089.

- 633 Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P (2012) Transcranial direct current
- 634 stimulation for depression: 3-week, randomised, sham-controlled trial. Br J Psychiatry 200:52-59.
- 635 Loo CK, Sachdev P, Martin D, Pigot M, Alonzo A, Malhi GS, Lagopoulos J, Mitchell P (2010) A double-
- blind, sham-controlled trial of transcranial direct current stimulation for the treatment of
- 637 depression. Int J Neuropsychopharmacol 13:61-69.
- Loo CK, Husain MM, McDonald WM, Aaronson S, O'Reardon JP, Alonzo A, Weickert CS, Martin DM,
- 639 McClintock SM, Mohan A (2018) International randomized-controlled trial of transcranial Direct
- 640 Current Stimulation in depression. Brain Stimul 11:125-133.
- 641 Mammarella N, Di Domenico A, Palumbo R, Fairfield B (2017) Self-generation and positivity effects
- following transcranial random noise stimulation in medial prefrontal cortex: A reality monitoringtask in older adults. Cortex 91:186-196.
- Mancuso M, Abbruzzese L, Canova S, Landi G, Rossi S, Santarnecchi E (2017) Transcranial random
- 645 noise stimulation does not improve behavioral and neurophysiological measures in patients with
- 646 subacute vegetative-unresponsive wakefulness state (VS-UWS). Front Hum Neurosci 11:524.
- McFadden JL, Borckardt JJ, George MS, Beam W (2011) Reducing procedural pain and discomfort
 associated with transcranial direct current stimulation. Brain Stimul 4:38-42.
- 649 Moffa AH, Brunoni AR, Fregni F, Palm U, Padberg F, Blumberger DM, Daskalakis ZJ, Bennabi D,
- Haffen E, Alonzo A (2017) Safety and acceptability of transcranial direct current stimulation for the
- acute treatment of major depressive episodes: Analysis of individual patient data. J Affect Disord221:1-5.
- 653 Moliadze V, Fritzsche G, Antal A (2014a) Comparing the efficacy of excitatory transcranial stimulation
- methods measuring motor evoked potentials. Neural plasticity 2014:837141-837141.
- 655 Moliadze V, Fritzsche G, Antal A (2014b) Comparing the efficacy of excitatory transcranial
- 656 stimulation methods measuring motor evoked potentials. Neural Plast 2014:837141-837141.
- 657 Montagne B, Kessels RP, De Haan EH, Perrett DI (2007) The Emotion Recognition Task: a paradigm to
- 658 measure the perception of facial emotional expressions at different intensities. Percept Mot Skills659 104:589-598.
- 660 Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J 661 Psychiatry 134:382-389.
- 662 Moss F, Ward LM, Sannita WG (2004) Stochastic resonance and sensory information processing: a 663 tutorial and review of application. Clin Neurophysiol 115:267-281.
- 664 Mutz J, Edgcumbe DR, Brunoni AR, Fu CHY (2018) Efficacy and acceptability of non-invasive brain
- 665 stimulation for the treatment of adult unipolar and bipolar depression: A systematic review and 666 meta-analysis of randomised sham-controlled trials. Neurosci Biobehav Rev 92:291-303.
- Nikolin S, Huggins C, Martin D, Alonzo A, Loo CK (2018) Safety of repeated sessions of transcranial
 direct current stimulation: A systematic review. Brain Stimulation 11:278-288.
- 669 Nitsche M, Paulus W (2001) Sustained excitability elevations induced by transcranial DC motor
- 670 cortex stimulation in humans. Neurology 57:1899-1901.
- 671 Nitsche MA, Cohen LG, Wassermann EM, Priori A, Lang N, Antal A, Paulus W, Hummel F, Boggio PS,
- 672 Fregni F, Pascual-Leone A (2008) Transcranial direct current stimulation: State of the art 2008. Brain
- 673 Stimul 1:206-223.
- Noda Y, Zomorrodi R, Vila-Rodriguez F, Downar J, Farzan F, Cash RF, Rajji TK, Daskalakis ZJ,
- Blumberger DM (2018) Impaired neuroplasticity in the prefrontal cortex in depression indexed
- 676 through paired associative stimulation. Depress Anxiety 35:448-456.
- 677 Palm U, Schiller C, Fintescu Z, Obermeier M, Keeser D, Reisinger E, Pogarell O, Nitsche M, Möller H-J,
- 678 Padberg F (2012) Transcranial direct current stimulation in treatment resistant depression: a
- 679 randomized double-blind, placebo-controlled study. Brain Stimul 5:242-251.
- 680 Palm U, Chalah MA, Padberg F, Al-Ani T, Abdellaoui M, Sorel M, Dimitri D, Creange A, Lefaucheur JP,
- 681 Ayache SS (2016) Effects of transcranial random noise stimulation (tRNS) on affect, pain and
- attention in multiple sclerosis. Restor Neurol Neurosci 34:189-199.

- 683 Pavan A, Ghin F, Contillo A, Milesi C, Campana G, Mather G (2019) Modulatory mechanisms
- underlying high-frequency transcranial random noise stimulation (hf-tRNS): A combined stochastic
 resonance and equivalent noise approach. Brain Stimul.
- Pittenger C, Duman RS (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms.
 Neuropsychopharmacol 33:88-109.
- 688 Player MJ, Taylor JL, Alonzo A, Loo CK (2012) Paired associative stimulation increases motor cortex
- 689 excitability more effectively than theta-burst stimulation. Clin Neurophysiol 123:2220-2226.
- 690 Player MJ, Taylor JL, Weickert CS, Alonzo A, Sachdev P, Martin D, Mitchell PB, Loo CK (2013)
- 691 Neuroplasticity in depressed individuals compared with healthy controls. Neuropsychopharmacol692 38:2101.
- 693 Player MJ, Taylor JL, Weickert CS, Alonzo A, Sachdev PS, Martin D, Mitchell PB, Loo CK (2014)
- 694 Increase in PAS-induced neuroplasticity after a treatment courseof transcranial direct current695 stimulation for depression. J Affect Disord 167:140-147.
- 696 Popescu T, Krause B, Terhune DB, Twose O, Page T, Humphreys G, Cohen Kadosh R (2016)
- Transcranial random noise stimulation mitigates increased difficulty in an arithmetic learning task.Neuropsychologia 81:255-264.
- 699 Rufener KS, Ruhnau P, Heinze H-J, Zaehle T (2017) Transcranial random noise stimulation (tRNS)
- shapes the processing of rapidly changing auditory information. Front Cell Neurosci 11:162.
- 701 Rufener KS, Geyer U, Janitzky K, Heinze HJ, Zaehle T (2018) Modulating auditory selective attention
- by non-invasive brain stimulation: Differential effects of transcutaneous vagal nerve stimulation and
 transcranial random noise stimulation. Eur J Neurosci 48:2301-2309.
- Ruff RM, Allen CC (1996) Ruff 2 and 7 Selective Attention Test Professional Manual. Odessa, FL:
- 705 Psychological Assessment Resources, Inc.
- 706 Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM,
- Warden D, Luther JF (2006a) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for
 depression. New England Journal of Medicine 354:1231-1242.
- 709 Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME,
- The America State of the Ameri
- 711 (2006b) Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several
- 712 Treatment Steps: A STAR*D Report. Am J Psychiatry 163:1905-1917.
- 713 Salemi G, Vazzoler G, Ragonese P, Bianchi A, Cosentino G, Croce G, Gangitano M, Portera E,
- Realmuto S, Fierro B, Brighina F (2019) Application of tRNS to improve multiple sclerosis fatigue: a
- 715 pilot, single-blind, sham-controlled study. J Neural Transm (Vienna).
- 716 Sampaio-Junior B, Tortella G, Borrione L, Moffa AH, Machado-Vieira R, Cretaz E, da Silva AF, Fraguas
- 717 R, Aparício LV, Klein I (2018) Efficacy and safety of transcranial direct current stimulation as an add-
- on treatment for bipolar depression: a randomized clinical trial. JAMA Psychiatry 75:158-166.
- 719 Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O
- 720 (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants.
- 721 Science 301:805-809.
- Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting
 parallel group randomised trials. BMC Med 8:18.
- Shalev N, De Wandel L, Dockree P, Demeyere N, Chechlacz M (2018) Beyond time and space: The
- effect of a lateralized sustained attention task and brain stimulation on spatial and selective
- 726 attention. Cortex 107:131-147.
- Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC
- 728 (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation
- of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 Suppl
- 730 20:22-33;quiz 34-57.
- 731 Smith A (1991) Symbol Digit Modalities Test. Los Angeles, CA: Western Psychological Services.

- 732 Snowball A, Tachtsidis I, Popescu T, Thompson J, Delazer M, Zamarian L, Zhu T, Kadosh RC (2013)
- Long-term enhancement of brain function and cognition using cognitive training and brain
- stimulation. Curr Biol 23:987-992.
- 735 Szymkowicz SM, McLaren ME, Suryadevara U, Woods AJ (2016) Transcranial Direct Current
- Stimulation Use in the Treatment of Neuropsychiatric Disorders: A Brief Review. Psychiatr Ann46:642-646.
- 738 Terney D, Chaieb L, Moliadze V, Antal A, Paulus W (2008) Increasing human brain excitability by
- transcranial high-frequency random noise stimulation. J Neurosci 28:14147-14155.
- 740 Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH,
- 741 Lebowitz B, McGrath PJ (2006) Evaluation of outcomes with citalopram for depression using
- 742 measurement-based care in STAR* D: implications for clinical practice. Am J Psychiatry 163:28-40.
- 743 Tyler SC, Conto F, Battelli L (2018) Rapid Improvement on a Temporal Attention Task within a Single
- 744 Session of High-frequency Transcranial Random Noise Stimulation. J Cogn Neurosci 30:656-666.
- van der Groen O, Wenderoth N (2017) Random noise stimulation of the cortex: stochastic resonance
- enhances central mechanisms of perception. Brain Stimul 10:e4.
- 747 Van der Groen O, Tang MF, Wenderoth N, Mattingley JB (2018) Stochastic resonance enhances the
- rate of evidence accumulation during combined brain stimulation and perceptual decision-making.
- 749 PLoS Comput Biol 14:e1006301.
- 750 Vanneste S, Fregni F, De Ridder D (2013) Head-to-head comparison of transcranial random noise
- stimulation, transcranial AC stimulation, and transcranial DC stimulation for tinnitus. Front
- 752 Psychiatry 4:158.
- 753 Wechsler D (2008) Wechsler Adult Intelligence Scale (4th ed.). San Antonio, TX: Pearson.

755 Supplementary Materials

756 Paired associative stimulation methods

757 Participants sat in a comfortable, relaxed position with both hands on a pillow. The 758 optimal site for eliciting motor evoked potentials (MEPs) in the right first dorsal interosseous 759 (FDI) muscle was first established and marked on the scalp. Each participant's resting motor 760 threshold (RMT) – defined as the minimum stimulus intensity to evoke MEPs of $\geq 50 \,\mu\text{V}$ in 761 the relaxed FDI in 5 out of 10 consecutive trials of single-pulse TMS – was then measured. 762 TMS intensity for evoking test MEPs was adjusted individually for each participant to elicit 763 an average 1 mV response. TMS intensity for testing MEPs was limited to a maximum of 764 130% of RMT even if the actual intensity needed to elicit a 1 mV response was greater. 765 For the stimulation protocol, single-pulse TMS (130% of RMT) to the FDI 766 representation on the left motor cortex was combined with electrical stimuli (200 µs duration, 767 300% perceptual threshold, DS7 stimulator; Digitimer Co. Ltd., Hertfordshire, UK) to the 768 right ulnar nerve proximal to the wrist. Two hundred pairs of stimuli (TMS and ulnar nerve) 769 were given at 0.25 Hz over \sim 13 minutes. In each pair, ulnar nerve stimulation preceded TMS 770 by 25 ms. Electrical stimuli were delivered occasionally to the right index finger during PAS. 771 Participants counted the stimuli and reported the number at the end of the session to ensure 772 sensory attention to the hand (Stefan et al., 2004). The MEPs recorded before and after PAS to assess cortical excitability consisted of testing blocks of 20 MEPs at a rate of 0.1 Hz. Two 773 774 blocks of MEPs were recorded at baseline. A block of MEPs was recorded immediately after 775 PAS and then every 10 mins for one hour. During all stimulation, EMG from the FDI was 776 monitored to ensure muscle relaxation. MEPs were discarded if EMG showed substantial 777 muscle activity (i.e. peak-to-peak amplitude $\geq 50 \ \mu V$) in the time window prior to the TMS 778 stimuli. Additionally, block-averaged MEP amplitudes were considered outliers if they were

- more than 4 standard deviations from the mean for active and sham tRNS conditions
- 780 combined.
- 781 EMG activity was recorded through Ag/AgCl surface electrodes over the right FDI. EMG
- 782 was amplified, bandpass filtered (16–1000 Hz), and digitized (2000 Hz) (Cambridge
- 783 Electronics Design, Cambridge, UK). TMS (Magstim 200 stimulator, Magstim Co.,
- 784 Whitland, UK) was applied using a 70-mm figure-of eight coil oriented with the handle
- 785 posterolateral, 45° to the parasagittal plane.

786 Supplementary Table S1. Schedule of assessments.

	Baseline	Sham-controlled phase Open-label ph						bel pha	hase Taper phase				
Week	Wk 0	Wk	Wk	Wk	Wk	Wk	Wk	Wk	Wk	Wk	Wk	Wk	Wk
Week	WK U	1	2	3	4	1	2	3	4	1	2	3	4
Session	Pre 1	1-5	6- 10	11- 15	16- 20	21- 25	26- 30	31- 35	36- 40	41	42	43	44
Mood Assessments													
MADRS	Х		Х		Х		Х		Х				Х
BDI-II	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
CGI-S	Х												
CGI-I			Х		Х		Х		Х				Х
Q-LES-SF	Х				Х				Х				Х
Neurophysiological Assessments													
PAS	Х				Х				Х				
Neuropsychological													
Assessments													
CVLT-II	Х				Х				Х				
Ruff 2 & 7	Х				Х				Х				
WAIS-IV Digit Span	Х				Х				Х				
SDMT	Х				Х				Х				
D-KEFS Verbal Fluency	Х				Х				Х				
CFQ	Х				Х				Х				

787 788 789 790 791 792 Wk: Week. MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-S: Clinician Global Impression Severity scale, is a 7-point clinician-rated scale ranked from 1-normal to 7-extremely ill. CGI-I: Clinician Global Improvement scale, is a 7-point clinician-rated scale ranked from 1-very much improved to 7-very much worse. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form. PAS: Paired associative stimulation. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult Intelligence Scale. SDMT: Symbol Digit

Modalities Test. D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire

793 Supplementary Table S2. MADRS mixed-effects repeated measures analyses

virg other covariates.

Results from MERM analyses during the sham-controlled phase to examine the impact of

796 medications and treatment expectations as covariates on mood outcomes (i.e. MADRS

797 scores).

	Covariate		Time		Condition		Time x Condition		
	corunate				0011	E		condition	
	F	р	F	р	F	р	F	р	
Baseline TEQ	0.28	0.599	40.93	<0.001	0.99	0.325	1.32	0.276	
Antidepressants	1.14	0.289	44.28	<0.001	2.03	0.160	1.11	0.335	
Lithium	3.73	0.058	44.20	<0.001	2.24	0.140	1.14	0.327	
Benzodiazepine*	2.48	0.120	44.24	<0.001	1.88	0.175	1.12	0.332	
Antipsychotics	1.78	0.188	44.22	<0.001	2.15	0.147	1.12	0.332	
Anticonvulsants	0.34	0.561	44.26	<0.001	2.10	0.152	1.12	0.332	

798 *Participants were required to cease benzodiazepine medication use prior to commencing the trial.

799 TEQ: Treatment Expectations Questionnaire

800 Supplementary Table S3. Mood, quality of life, neuroplasticity and

801 neuropsychological outcome measures.

- 802 Results from MERM analyses during the acute daily treatment phases combined (i.e. tRNS
- 803 received during the sham-controlled and open-label phases).

	Con	Condition		Time		Time × Condition	
	F	р	F	р	F	р	
Mood Assessments (m, SEM)							
MADRS	1.09	0.300	29.39	<0.001	0.75	0.560	
BDI-II	2.38	0.128	17.60	<0.001	1.00	0.447	
CGI-I	6.02	0.017	15.84	<0.001	1.72	0.173	
Q-LES-SF	0.00	0.967	30.00	<0.001	1.39	0.257	
Neuroplasticity Assessments (m, SEM)							
PAS: MEP amplitude	0.40	0.530	2.11	0.135	0.72	0.193	
Neuropsychological Assessments (m, SEM)							
CVLT-II: Trial 1-5 total recall t-score	4.47	0.036	3.12	0.046	0.17	0.844	
CVLT-II: Long delay free recall z-score	5.40	0.021	3.03	0.051	0.23	0.799	
D-KEFS: Letter fluency scaled score	2.70	0.102	0.14	0.867	0.38	0.683	
D-KEFS: Category fluency scaled score	1.97	0.165	0.74	0.477	1.69	0.190	
D-KEFS: Category switching total scaled score	2.94	0.088	1.07	0.346	0.24	0.786	
Ruff 2 & 7: Total speed t-score	2.94	0.088	3.50	0.032	0.06	0.946	
Ruff 2 & 7: Total accuracy t-score	0.80	0.372	0.73	0.482	0.22	0.805	
SDMT: Total correct z-score	3.58	0.063	2.80	0.065	1.11	0.335	
WAIS-IV Digit Span: Total correct scaled score	17.17	<0.001	2.05	0.132	0.06	0.945	
CFQ: Total score	0.20	0.659	0.12	0.891	0.45	0.639	

804 MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-I: Clinician Global

805 Impression Improvement scale, is a 7-point clinician-rated scale ranked from 1-very much improved to 7-very much worse.

806 Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. PAS: Paired associative stimulation.

807 MEP: motor evoked potential. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult Intelligence Scale. SDMT:

808 Symbol Digit Modalities Test. D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire.

809 m: Mean. SEM: Standard error of measures

810 Supplementary Table S4. Intention-to-treat analyses.

- 811 Estimated marginal means and results from MERM analyses during the sham-controlled
- 812 phase, including the following covariates: Maudsley staging parameters total score as a
- 813 measure of treatment resistance, and antidepressant use. Neuroplasticity and
- 814 neuropsychological outcome measures are reported using an intention-to-treat analysis
- 815 approach.

	Baseline		Week 2 Week 4		Condition		Time		Time × Conditio n			
	Sham	Activ e	Sh am	Act ive	Sham	Active	F	р	F	р	F	р
Neuroplasticity Assessments												
(<i>m</i> , <i>SEM</i>)												
PAS: MEP amplitude	1.24 (0.10)	1.21 (0.12)	-	-	1.31 (0.09)	1.40 (0.10)	0.0 8	0.7 80	1. 63	0.2 09	0. 33	0.5 70
Neuropsychological		. ,										
Assessments (m, SEM)												
CVLT-II: Trial 1-5 total	45.7	48.8			46.3	49.7	2.2	0.1	0.	0.7	0.	0.9
recall t-score	(2.2)	(2.2)	-	-	(2.3)	(2.1)	9	33	10	51	01	43
CVLT-II: Long delay free	-0.42	0.03			-0.64	-0.39	2.8	0.0	1.	0.1	0.	0.0
recall z-score	(0.21)	(0.21)	-	-	(0.22)	(0.21)	2	96	93	67	23	35
D-KEFS: Letter fluency	11.2	11.6			10.9	11.9	1.1	0.2	0.	0.9	0.	0.0
scaled score	(0.7)	(0.7)	-	-	(0.7)	(0.7)	8	80	00	91	21	48
D-KEFS: Category fluency	10.3	10.9			9.9	11.7	1.6	0.2	0.	0.7	1.	0.
scaled score	(0.8)	(0.8)	-	-	(0.8)	(0.8)	4	04	07	89	78	87
D-KEFS: Category	10.0	11.2			9.6	10.6	3.6	0.0	0.	0.4	0.	0.
switching total scaled score	(0.6)	(0.6)	-	-	(0.6)	(0.6)	1	60	56	54	04	50
Ruff 2 & 7: Total speed t-	47.4	50.6			51.4	53.6	2.1	0.1	2.	0.0	0.	0.
score	(1.9)	(1.9)	-	-	(1.9)	(1.9)	7	44	97	87	07	89
Ruff 2 & 7: Total accuracy	49.6	46.5			50.4	48.7	1.0	0.3	0.	0.5	0.	0.′
t-score	(2.3)	(2.3)	-	-	(2.4)	(2.3)	7	02	36	47	09	64
SDMT: Total correct z-	-0.31	0.22			0.00	0.40	4.1	0.0	4.	0.0	0.	0.4
score	(0.17)	(0.18)	-	-	(0.18)	(0.17)	0	47	38	39	53	69
WAIS-IV Digit Span: Total	9.7	11.5			10.5	12.6	13.	<0.	2.	0.1	0.	0.
correct scaled score	(0.5)	(0.5)	-	-	(0.6)	(0.5)	67	001	50	16	09	71
CFQ: Total score	50.1	46.6			49.9	50.0	0.6	0.4	0.	0.5	0.	0.4
CrQ. Total scole	(2.2)	(2.2)	-	-	(2.3)	(2.2)	1	35	45	01	70	- 06

816 MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-I: Clinician Global

817 Impression Improvement scale, is a 7-point clinician-rated scale ranked

818 from 1-very much improved to 7-very much worse. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire –

819 Short Form. PAS: Paired associative stimulation. MEP: motor evoked potential. CVLT: California Verbal Learning Test.

820 WAIS: Wechsler Adult Intelligence Scale. SDMT: Symbol Digit Modalities Test. D-KEFS: Delis-Kaplan Executive

821 Function System. CFQ: Cognitive Failures Questionnaire. m: Mean. SEM: Standard error of measures

822 Supplementary Figure S1. Treatment Expectations Questionnaire

	Treatment Expec	tations Question	naire – Views on	DCS						
Participant ID	Date	Sess	ion							
Please answer the following questions about how effective you think DCS will be in helping improve some symptoms of depression you may be experiencing. If you are not currently experiencing the symptom, please circle NA.										
1) How effective do you think DCS will be for <u>improving</u> your sleep?										
1	2	3	4	5	NA					
Not effective a all	t Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with sleep					
2) How effective	ve do you think DC	S will be for <u>redu</u>	<u>cing</u> feelings of sa	ndness?						
1	2	3	4	5	NA					
Not effective a all	t Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with feeling sad					
3) How effective	ve do you think DC	S will be for <u>imp</u> i	oving your appet	ite?						
1	2	3	4	5	NA					
Not effective a	t Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with					
					my appetite					
4) How effective do you think DCS will be for <u>improving</u> your concentration/decision making?										
1	2	3	4	5	NA					
Not effective a all	t Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with concentration/					
					decision making					

5) How effective do you think DCS will be for reducing thoughts of death or suicide?

1	2	3	4	5	NA
Not effective a all	at Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with
					thoughts of death or suicide
	ve do you think DC r ability to enjoy th		oving your genera	al interest in thi	ngs
1	2	3	4	5	NA
Not effective a all	at Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with general interest/ enjoying things
7) How effecti	ve do you think DC	S will be for <u>impr</u>	oving your energ	y level?	
7) How effecti 1	ve do you think DC	S will be for <u>impr</u> 3	<u>oving</u> your energ 4	y level? 5	NA
1 Not effective a	2 at Only a little bit	3 Moderately		5 Extremely	NA I don't have
1	2	3	4	5	
 Not effective a all 8) OVERALL 	2 at Only a little bit	3 Moderately Effective you think DCS wit	4 Quite Effective	5 Extremely Effective	I don't have problems with my
 Not effective a all 8) OVERALL 	2 at Only a little bit Effective	3 Moderately Effective you think DCS wit	4 Quite Effective	5 Extremely Effective	I don't have problems with my

9) Are there any particular reasons why you believe DCS will or will not be effective?


END OF QUESTIONNAIRE

826 Supplementary Figure S2. tRNS Side Effects Questionnaire

Side Effect	Before	During	After	Severity*	Causality [#]
Redness anode cathode					
Tingling/Itching/Burning/Pain anode cathode					
Nausea					
Lightheadedness/Dizziness					
Headache					
Blurred Vision					
Fatigue					
Other:					

*Severity: 1 = Mild; 2 = Moderate; 3 = Severe. If participant had a side effect after the previous tRNS session, ask when it started and for how long and record in the 'Before' column. #Causality: 1 = Probably Related; 2 = Possibly Related; 3 = Probably Not Related; 4 = Not Related


828 Supplementary Figure S3. CONSORT flow diagram.





854 Supplementary Figure S4. Follow-up mood outcome measures.

Graphs showing mood and quality of life scores (unadjusted means \pm SD) from baseline up to


- the 9-month follow-up assessment following completion of the open-label phase. Sample
- sizes used for the calculation of summary statistics are presented for each time-point. A)
- 858 Montgomery-Asberg Depression Rating Scale (MADRS) scores. B) Beck Depression
- 859 Inventory (BDI-II) scores. C) Clinician Global Impression Severity (CGI-S) at baseline, and
- 860 CGI-Improvement (CGI-I) scores; the CGI-S is a 7-point clinician-rated scale ranked from 1-
- 861 normal (not at all ill) to 7-among most extremely ill patients. The CGI-I is a 7-point clinician-
- rated scale ranked from 1-very much improved to 7-very much worse. D) Quality of Life
- 863 Enjoyment and Satisfaction Questionnaire Short Form scores (Q-LES-SF).















869 Supplementary Figure S5. Paired associative stimulation.

Group data (estimated marginal means ± bootstrapped 95% confidence intervals) showing the
time course of changes in the amplitude of motor evoked potentials (MEPs) immediately
after the PAS conditioning stimulus. Post-PAS MEP amplitudes were normalized to pre-PAS
amplitudes for each participant. A) MEP amplitude changes at baseline, prior to the course of
tRNS. B) MEP amplitude changes following the 4-week sham-controlled phase.



876 Supplementary Figure S6. Correlation between mood and neuroplasticity.

- 877 There was no association between percent change in motor evoked potentials (MEPs)
- following paired associative stimulation (PAS) and percent change in mood scores over the
- 879 course of the sham-controlled phase (r = -0.02, p = 0.905).



880